Bolt Biotherapeutics (BOLT) COO Yonehiro Grant Sells Shares

What Happened
Yonehiro Grant, Chief Operating Officer of Bolt Biotherapeutics (BOLT), sold a total of 13,176 company shares in three open-market transactions between Sept. 16–18, 2026. The sales were: 1,417 shares at a weighted average $3.77 ($5,348), 4,909 shares at $3.32 ($16,290), and 6,850 shares at $3.24 ($22,169), for combined proceeds of approximately $43,807. These were dispositions (sales), not purchases.

Key Details

• Transaction dates and reported weighted-average prices:
  • 2026-09-16: 1,417 shares sold @ $3.77 — $5,348 (footnote F1; actual sale prices ranged $3.60–$4.14)
  • 2026-09-17: 4,909 shares sold @ $3.32 — $16,290 (footnote F2; actual sale prices ranged $3.22–$3.67)
  • 2026-09-18: 6,850 shares sold @ $3.24 — $22,169 (footnote F3; actual sale prices ranged $3.15–$3.41)
• Purpose: Footnotes state these sales were to cover tax withholding obligations from the vesting of restricted stock units granted Oct. 22, 2025.
• Shares owned after the transactions: Not specified in the provided filing summary.
• Filing timeliness: The Form 4 was filed on 2026-09-21, after the transactions (9/16–9/18). This is later than the standard Form 4 reporting window (generally two business days), so the filing is marked late.
• Additional note: The reporting person offers to provide detailed breakdowns of how many shares were sold at each specific price to the SEC or issuer upon request.

Context
Sales to cover tax withholding on RSU vesting are common and typically routine administrative transactions rather than direct signals of executive sentiment about the company. The transactions were coded as sales (S) and accompanied by footnotes explaining the tax-withholding purpose.